BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38165164)

  • 1. Impact factors of benefiting from initial 131 I ablation in patients with intermediate-risk differentiated thyroid carcinoma: a study based on a re-evaluation of therapeutic response.
    Ren L; Hu Y; Hu Y; Xiao D; Sun J; Zhu B; Zhang C
    Nucl Med Commun; 2024 Mar; 45(3):188-195. PubMed ID: 38165164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. UNFAVORABLE RESPONSES TO RADIOIODINE THERAPY IN N1B PAPILLARY THYROID CANCER: A PROPENSITY SCORE MATCHING STUDY.
    Liu YQ; Li H; Liu JR; Lin YS
    Endocr Pract; 2019 Dec; 25(12):1286-1294. PubMed ID: 31412228
    [No Abstract]   [Full Text] [Related]  

  • 3. Prognostic value of post-ablation stimulated thyroglobulin in differentiated thyroid cancer patients with biochemical incomplete response: a bi-center observational study.
    Wang Y; Wu J; Jiang L; Zhang X; Liu B
    Endocrine; 2022 Apr; 76(1):109-115. PubMed ID: 35094313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum thyrotropin level of 30 μIU/mL is inadequate for preablative thyroglobulin to serve as a prognostic marker for differentiated thyroid cancer.
    Zhao T; Liang J; Guo Z; Li J; Lin Y
    Endocrine; 2016 Jul; 53(1):166-73. PubMed ID: 26782372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delayed Initial Radioiodine Adjuvant Therapy Does Affect Biochemical Response in Intermediate- to High-Risk Differentiated Thyroid Cancer.
    Yu F; Li X; Ji Y; Tan J; Zhang G; Wang P; He Y; Wang R
    Front Endocrinol (Lausanne); 2021; 12():743310. PubMed ID: 34858329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delayed initial radioiodine therapy related to incomplete response in low- to intermediate-risk differentiated thyroid cancer.
    Li H; Zhang YQ; Wang C; Zhang X; Li X; Lin YS
    Clin Endocrinol (Oxf); 2018 Apr; 88(4):601-606. PubMed ID: 29338092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Importance of postoperative stimulated thyroglobulin level at the time of 131I ablation therapy for differentiated thyroid cancer.
    Hasbek Z; Turgut B; Kilicli F; Altuntas EE; Yucel B
    Asian Pac J Cancer Prev; 2014; 15(6):2523-7. PubMed ID: 24761858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age, thyroglobulin levels and ATA risk stratification predict 10-year survival rate of differentiated thyroid cancer patients.
    Kelly A; Barres B; Kwiatkowski F; Batisse-Lignier M; Aubert B; Valla C; Somda F; Cachin F; Tauveron I; Maqdasy S
    PLoS One; 2019; 14(8):e0221298. PubMed ID: 31425569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Negative remnant
    Lan W; Gege Z; Ningning L; Qiang W; Lin B; Qingjie M; Bin J
    Ann Nucl Med; 2019 Feb; 33(2):112-118. PubMed ID: 30374858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic Risk Estimates of Outcome in Chinese Patients with Well-Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation.
    Shen FC; Hsieh CJ; Huang IC; Chang YH; Wang PW
    Thyroid; 2017 Apr; 27(4):531-536. PubMed ID: 28007013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer.
    Iizuka Y; Katagiri T; Ogura K; Mizowaki T
    Ann Nucl Med; 2019 Jul; 33(7):495-501. PubMed ID: 30955202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re-ablation I-131 activity does not predict treatment success in low- and intermediate-risk patients with differentiated thyroid carcinoma.
    Prpic M; Kruljac I; Kust D; Kirigin LS; Jukic T; Dabelic N; Bolanca A; Kusic Z
    Endocrine; 2016 Jun; 52(3):602-8. PubMed ID: 26732041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Patients With Low- to Intermediate-Risk Thyroid Cancer, a Preablative Thyrotropin Level of 30 μIU/mL Is Not Adequate to Achieve Better Response to 131I Therapy.
    Zhao T; Liang J; Guo Z; Li T; Lin Y
    Clin Nucl Med; 2016 Jun; 41(6):454-8. PubMed ID: 26914559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes after radioiodine ablation in patients with thyroid cancer: Long-term follow-up of a Chinese randomized clinicaltrial.
    Dong P; Qu Y; Yang L; Xiao L; Huang R; Li L
    Clin Endocrinol (Oxf); 2021 Nov; 95(5):782-789. PubMed ID: 34368999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thyroglobulin levels measured at the time of remnant ablation to predict response to treatment in differentiated thyroid cancer after thyroid hormone withdrawal or recombinant human TSH.
    Pitoia F; Abelleira E; Cross G
    Endocrine; 2017 Jan; 55(1):200-208. PubMed ID: 27655291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preablative Stimulated Thyroglobulin Correlates to New Therapy Response System in Differentiated Thyroid Cancer.
    Yang X; Liang J; Li T; Zhao T; Lin Y
    J Clin Endocrinol Metab; 2016 Mar; 101(3):1307-13. PubMed ID: 26789779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Applying postoperative radioiodine therapy before 3 months seems to decrease ablation success in patients with differentiated thyroid carcinoma.
    Özdoğan Ö; Aksu A; Doğan E; Bülbül O; Güray Durak M; Sevinç Aİ; Bayraktar F; İkiz AÖ
    Ann Nucl Med; 2021 Feb; 35(2):223-231. PubMed ID: 33389664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioiodine ablation with 1,850 MBq in association with rhTSH in patients with differentiated thyroid cancer.
    Tresoldi AS; Sburlati LF; Rodari M; Schinkelshoek MS; Perrino M; De Leo S; Montefusco L; Colombo P; Arosio M; Lania AGA; Fugazzola L; Chiti A
    J Endocrinol Invest; 2014 Aug; 37(8):709-714. PubMed ID: 24844565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system.
    Tuttle RM; Tala H; Shah J; Leboeuf R; Ghossein R; Gonen M; Brokhin M; Omry G; Fagin JA; Shaha A
    Thyroid; 2010 Dec; 20(12):1341-9. PubMed ID: 21034228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early preablation rhTSH-stimulated thyroglobulin predicts outcome of differentiated thyroid cancer (DTC) patients.
    Campennì A; Ruggeri RM; Siracusa M; Comis AD; Romano D; Vento A; Lanzafame H; Capoccetti F; Alibrandi A; Baldari S; Giovanella L
    Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2466-2475. PubMed ID: 33416957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.